Interim Financial Report – Half year results as of June 30, 2018 June 30, 20180CommentsInterim Financial Report - Half year results as of June 30, 2018 Read More
ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC June 21, 20180CommentsEN Read More
ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME) May 25, 20180CommentsEN Read More
ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018 May 23, 20180CommentsEN Read More
ThromboGenics Presenting Industry Expertise and Developments at Bio€quity Europe and Knowledge for Growth meetings in Ghent, Belgium May 14, 20180CommentsEN Read More
ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combo with anti-VEGF (ranibizumab) for treatment of DME April 27, 20180CommentsEN Read More
ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149 April 6, 20180CommentsEN Read More
ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317 for the Treatment of Diabetic Macular Edema (DME) April 4, 20180CommentsEN Read More
NOVARTIS PHARMA AG HOLDING 5.69% OF THROMBOGENICS EQUITY CAPITAL January 26, 20180CommentsEN NL Read More
ThromboGenics – Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy Discontinued due to Slow Recruitment Rate December 8, 20170CommentsEN Read More
